• Platform
    • The SOPHiA DDM™ Platform
    • Genomics
    • Radiomics
    • Multimodal
    • Alamut Visual Plus™
    • OncoPortal™ Plus
    • SOPHiA Integrated Solutions
  • Solutions
    • Clinical
    • Oncology
    • Solid Tumors
    • Blood Cancers
    • Hereditary Cancers
    • CE-IVD Products
    • Rare and Inherited Diseases
    • Cardiovascular Diseases
    • Neurological Disorders
    • Metabolism
    • Rare Diseases
    • BioPharma
  • Resources
    • Case Studies
    • Publications
    • Webinars
    • Science Hub
  • Company
    • About Us
    • Leadership Team
    • Investors
    • Press Releases
    • Press Kit
    • Blog
    • Events
    • Careers
    • Partner With Us
    • Contact Us
  • REQUEST A DEMO
SOPHiA GENETICS
Search

More results...

Generic filters
SOPHiA GENETICS
  • Platform
    • The Sophia ddm platform
      • Genomics
      • Radiomics
      • Multimodal
    • .
      • Alamut Visual Plus™
      • OncoPortal™ Plus
      • SOPHiA Integrated Solutions
  • Solutions
    • Clinical
      • Oncology
        • Solid Tumors
        • Blood Cancers
        • Hereditary Cancers
        • CE-IVD Products
    • .
      • Rare and Inherited Diseases
        • Cardiovascular Diseases
        • Metabolism
        • Neurological Disorders
        • Rare Diseases
    • BioPharma
      • Discover BioPharma
  • Resources
    • Case Studies
    • Publications
    • Webinars
    • Science Hub
  • Company
    • About SOPHiA GENETICS
      • About Us
      • Leadership Team
      • Investors
      • Press Releases
      • Press Kit
    • Useful Links
      • Blog
      • Events
      • Careers
      • Partner With Us
      • Contact Us
  • REQUEST A DEMO
  • SIGN IN
  • Home
  • 5
  • Documents
  • 5
  • Primer Mix Illumina Library Amp_IT

Primer Mix Illumina Library Amp_IT

by [email protected] | May 19, 2022

File Type: pdf
Categories: Safety Data Sheet
Tags: Italian

Recent Posts

  • Seven reasons to choose SOPHiA DDM Dx RNAtarget Oncology Solution for gene fusion detection
  • Detecting HRD in ovarian cancers using a deep learning solution based on low pass whole-genome sequencing
  • RNA analyses: Overcome the challenges of novel fusion detection
  • Food for thought from ASCO 2022: breaking boundaries in breast cancer research
  • AMP 2022

Recent Comments

    logo footer
    Platform

    The SOPHiA DDM™ Platform
    Genomics
    Radiomics
    Multimodal
    Alamut Visual Plus™
    OncoPortal™ Plus
    SOPHiA Integrated Solutions

    SOLUTIONS

    Oncology
    Rare and Inherited Diseases
    Cardiology
    Neurological Disorders
    Metabolism
    BioPharma

    RESOURCES

    Publications
    Case Studies
    Webinars
    Science Hub

    Company

    About Us
    Leadership Team
    Investors
    Press Releases
    Press Kit
    Blog

    Company

    Events
    Careers
    Partner With Us
    Contact Us
    Request A Demo

    © 2021 SOPHiA GENETICS. All rights reserved. Privacy Policy | Terms of Use | Legal | Sitemap
    • Follow
    • Follow
    • Follow
    • Follow
    • Follow

    SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
    SOPHiA Hereditary Cancer Solution, SOPHiA Myeloid Solution, SOPHiA Solid Tumor Solution are available as CE-IVD product for In Vitro Diagnostic Use in Europe, Turkey and Israel. Information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

    All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

    Somatic gene variant annotations and related content have been powered by, without limitation, The Jackson Laboratory Clinical Knowledgebase (JAX-CKB™).

    SOPHiA GENETICS
    Platform

    The SOPHiA DDM™ Platform
    Genomics
    Radiomics
    Multimodal
    Alamut Visual Plus™
    OncoPortal™ Plus
    SOPHiA Integrated Solutions

    SOLUTIONS

    Oncology
    Rare and Inherited Diseases
    Cardiology
    Neurological Disorders
    Metabolism
    BioPharma

    RESOURCES

    Publications
    Case Studies
    Webinars
    Science Hub

    Company

    About Us
    Leadership Team
    Investors
    Press Releases
    Press Kit
    Blog
    Events
    Careers
    Partner With Us
    Contact Us
    Request A Demo

    © 2021 SOPHiA GENETICS. All rights reserved.
    Privacy Policy | Terms of Use | Legal | Sitemap
    • Follow
    • Follow
    • Follow
    • Follow
    • Follow

    SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
    SOPHiA Hereditary Cancer Solution, SOPHiA Myeloid Solution, SOPHiA Solid Tumor Solution are available as CE-IVD product for In Vitro Diagnostic Use in Europe, Turkey and Israel. Information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

    All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

    Somatic gene variant annotations and related content have been powered by, without limitation, The Jackson Laboratory Clinical Knowledgebase (JAX-CKB™).